IPP Bureau
Lupin tops world pharma and all Indian sectors in S&P ESG rankings
By IPP Bureau - February 28, 2026
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
By IPP Bureau - February 28, 2026
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe
By IPP Bureau - February 28, 2026
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Thermo Fisher launches genetic test to personalize transplant drug dosing
By IPP Bureau - February 28, 2026
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial
By IPP Bureau - February 28, 2026
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Novartis completes $12 billion acquisition of Avidity Biosciences
By IPP Bureau - February 28, 2026
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer
By IPP Bureau - February 28, 2026
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
Combination therapy cuts death Risk in advanced prostate cancer: PEACE-3 trial
By IPP Bureau - February 28, 2026
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
Novartis’ remibrutinib bags positive CHMP opinion for chronic urticaria
By IPP Bureau - February 28, 2026
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Synthekine teams up with Merck to test breakthrough lung cancer combo
By IPP Bureau - February 28, 2026
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states
By IPP Bureau - February 27, 2026
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%
By IPP Bureau - February 27, 2026
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer
By IPP Bureau - February 27, 2026
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
By IPP Bureau - February 27, 2026
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
